XNAS · Biotechnology
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$102.98+0.06%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
61/100
Positive
Score components
TickerWhale View
Halozyme Therapeutics scores 61 out of 100 overall, which we rate positive. Quality & growth is its strongest area and Risk its weakest.
What helps
- Quality & growth
- Valuation
- Sentiment Signal
What to watch
- Technical
- Risk
Quality & growth
30%95Strong
- Revenue growth 41.2%
- EPS growth -22.4%
Valuation
25%66Positive
- P/E 30.2
- EV/Sales 8.7
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#45 / 139sector rank by TickerWhale Score
TickerWhale Score 61 vs sector average 54.6 (+6.4)
Revenue growth (industry)Top 42%
Gross margin (industry)Top 67%
Return on equity (industry)Top 2%
P/E (industry)Cheaper than 58%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
44/100Weak vs universe
Ranks 44th of 100 covered names on our technical composite — the composite itself scores 53/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
3 buy · 5 sell · 0 neutral of 8 votes
TickerWhale rates HALO's technical setup weak — 44th percentile of the covered universe. Classic chart indicators lean sell, pointing the same way.
Moving averages
3 / 9constructive
- vs 200-day+21.2%
- vs 50-day-10.5%
Momentum
Constructive
- RSI (14)29 · buy
- Stochasticbuy
- CCIsell
- Williams %Rbuy
Trend
Weak
- ADX (14) trend strength44· trending
- MACD (12,26,9)sell(histogram -3.561)
How the classic verdict is reached
Moving averages (9) agree on sell — 3 buy vs 6 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 4 sell · 0 neutral.
Result — 3 buy vs 5 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)30.2
- P/S (TTM)7.5
- P/B87.0
- EV/EBITDA—
- EV/Sales8.7
- PEG—
Profitability & returns
- Gross margin82.4%
- Net margin24.9%
- ROE227.8%
- Debt/Equity14.96
Growth
- Revenue growth (YoY)41.1%
- EPS growth (YoY)-22.4%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $12.5B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HALOCurrentHalozyme Therapeutics | 61 | 53 | 30.2 | — | 87.0 | 8.7 | $102.98 | +0.06% | +41.1% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.